indicated drugs at 37°C for 6 h, the following day. Luciferase assay was performed by using dual luciferase assay kit (Promega, Madison, WI) according to its instruction. Renilla luciferase (phRL-TK, Promega) activity was measured for normalizing the transfection efficiency. The luciferase activity was measured using a luminometer (GENE LIGHT 55, Microtech Nition, Funabashi, Japan). 
Adenoviral infection. Adenoviruses encoding carboxyl terminal regions of Gα
q (Gα q -ct, amino acids 305-359), Gα 12 (Gα 12 -ct, amino acids 325-379) and Gα 13 (Gα 13 -ct, amino acids 322-378) were created in our laboratory. The expressions of those genes are regulated by CMV promoter, their products putatively block G protein coupling with their corresponding receptors (Arai et al., 2003) . Each adenoviral vector contains both G-protein-ct and GFP that is upstream of the G-protein-ct, and each entity is under a control of CMV promoter. 1321N1 cells were infected with the indicated virus at 75 MOI for a day. Then the medium was replaced with serum-free medium the next day, and the cells were cultured This article has not been copyedited and formatted. The final version may differ from this version. overnight. At the time of drug incubation, more than 90% of the cells were GFP-positive.
SDS-polyacrylamide gel electrophoresis and immunoblotting. Samples used for
immunoblotting were prepared as follows. 1321N1 cells were seeded onto 6-well plates at a density of 1 x 10 6 (cells/well). The cells were cultured overnight in serum-free DMEM, then drugs were added for various periods of time. The incubation medium was aspirated after the reaction, and the cells were dissolved in Laemmli sample buffer (final concentration, Tris-HCl 75 mM, SDS 2%, glycerol 15%, 2-mercaptoethanol 3%, pH 6.8), and boiled at 95°C for 5 min.
Electrophoresis was performed on 11% acrylamide gels. Proteins were transferred electrically from the gel onto a polyvinylidene difluoride membrane (Millipore, Bedford, MA) by the semi-dry blotting method. The blots were blocked for 40 min with 5% skim-milk in anti-phospho-CREB (Ser 133) antibody or anti-CREB antibody (1:1000 dilution)) overnight at 4°C. The blots were washed several times and then incubated at 25°C for 2 h with a 1:3,000 dilution of secondary antibody (HRP-conjugated anti-rabbit IgG antibody). Blots were developed using an enhanced chemiluminescence assay kit (Amersham Biosciences), and visualized by chemiluminescence on Hyper-film ECL. The densities of the bands corresponding to CREB, ERK, p38 MAPK were analyzed by densitometry (NIH image) and the data were expressed as a ratio to their total proteins.
Statistical methods. Data were expressed as the mean values + S.E.M, and the significant differences were analyzed by Student t-test or Tukey's method for multiple-comparisons.
This article has not been copyedited and formatted. The final version may differ from this version. 
Results
U46619 enhances IL-6 production in 1321N1 cells. We investigated the biosynthesis of IL-6. 1321N1 cells were stimulated with TP agonist, U46619, then IL-6 secretion was examined by sandwich-ELISA (Fig. 1A) . U46619 significantly increased IL-6 secretion from 1321N1 cells in a concentration-dependent manner, that was inhibited by TP antagonist, SQ29548. Adenylyl cyclase activator, forskolin and cAMP analog, dbcAMP also promoted IL-6 secretion 1.6 fold and 2.9 fold, respectively (data not shown). U46619 (10 µM) also enhanced IL-6 gene expression (5.8 fold), and this effect was abolished by SQ29548 (1 µM) again (Fig. 1B) . Carbachol (10 µM), did not affect IL-6 gene expression. Forskolin and a PKC activator, PMA, enhanced IL-6 expression 4.5 fold and 7.0 fold in the same condition, respectively (Fig. 1B ). U46619 and SQ29548 have low affinity to other prostanoid receptors such as EP 4 (Kiriyama et al., 1997) , and it is also known that prostaglandin E 2 induces IL-6 release in U373 MG human astrocytoma cells (Fiebich et al., 2001) . To avoid the possibility that the effect of U46619 on IL-6 induction is mediated by EPs, we tested prostaglandin E 2 .
U46619-induced IL-6 expression was completely blocked by SQ29548 (3% of U46619 alone), while most part of the effect of prostaglandin E 2 was not blocked by SQ29548 (82% of prostaglandin E 2 alone) (Fig. 1C) . Cholera toxin as a positive control enhanced IL-6 expression 13.2 fold (Fig. 1C ). This result indicates that effect of U46619 is mediated by TPs.
To examine the IL-6 promoter activity, plasmid encoding wild type IL-6 promoter (-1039~+1) linked to luciferase gene was transfected into 1321N1 cells, and luciferase activity was measured (Fig. 1D ). U46619 (10 µM) as well as forskolin (10 µM) significantly enhanced IL-6 promoter activity. Furthermore, GFAP-positive cultured mouse astrocytes ( Fig. 2A) were This article has not been copyedited and formatted. The final version may differ from this version. stimulated with U46619 to determine whether IL-6 enhancement is 1321N1 cell-specific or not.
As expected, U46619 (10 µM) similarly promoted IL-6 gene expression (2.7 fold) in astrocytes as dbcAMP (2.1 fold), and the effect of U46619 was mostly reversed by SQ29548 (12% of dbcAMP alone) (Fig. 2B ). Taken together, these results suggest that U46619 enhances the secretion of IL-6 from 1321N1 cells accompanied with an increase in IL-6 gene expression. pCRE-luciferase plasmid was transfected into 1321N1 cells, then newly induced luciferase activity was regarded as the CREB transcriptional activity. U46619 (10 µM) and forskolin (10 µM) significantly increased CRE activity (Fig. 3A) . Next, to confirm the specificity of CRE in enhanced IL-6 gene expression, we utilized the IL-6 promoter-luciferase plasmid harboring a mutant CRE in the IL-6 promoter region (from ATGACGTCA to ATCGATCCA). The effect of U46619 on IL-6 promoter activity was completely abolished by mutation of CRE as in the case of forskolin (Fig. 3B) (CaMK inhibitor; 10 µM) for 15 min, then, they were stimulated with U46619 (10 µM) for 6 h ( Fig. 4A ). The U46619-induced CRE activation was significantly blocked by H89 and SB203580. Carbachol (10 or 100 µM) did not increase the CRE activity. Since H89 has been reported to inhibit MSK as well as PKA (Davies et al., 2000) , another PKA inhibitor KT5720 was tested. KT5720 (2 µM) also inhibited the CRE activity significantly (Fig. 4B ). Increase in CRE activity by U46619 was also blocked by SQ29548 (2 µM) and lower concentration of SB203580 (3 µM) (Fig. 4C ). Furthermore, MSK 1 wild type and the kinase-dead mutant (D195A and D565A) were overexpressed in 1321N1 cells, and CRE activity was measured (Fig. 4D) . The MSK 1 kinase-dead mutant partially but significantly attenuated the ability of U46619 to increase the CRE activity. CREB family members including CREB, activating transcription factor 1 and CRE modulator binds to CRE. To investigate whether CREB is involved in this process, CREB phosphorylation at Ser 133 was monitored. This phosphorylation site can be regarded as an index of CREB activation. The CREB phosphorylation by U46619 via TPs was observed ( suggest that CREB activation by U46619 is mediated by PKA and p38 MAPK/MSK pathways.
Next, the effects of these kinase inhibitors on IL-6 gene expression were investigated. H89 (10 µM) and SB203580 (30 µM) decreased IL-6 promoter activity accelerated by U46619 (10 µM)
( Fig. 6A ), similar to the inhibition of CRE activity shown in Fig. 4A . The effect of U46619 was also significantly inhibited by SQ29548 (2 µM), SB203580 (3 µM) and overexpressing a physiological PKA pseudosubstrate peptide, PKI (Fig. 6B) . Furthermore, when 1321N1 cells were pretreated with SB203580 (30 µM), IL-6 gene expression induced by U46619 (10 µM)
was largely suppressed (21% of U46619 alone), as determined by RT-PCR (Fig. 6C ). Since the involvement of p38 MAPK in TP-mediated IL-6 expression was suggested, we examined whether p38 MAPK was activated by U46619. When 1321N1 cells were incubated with U46619 (10 µM) for 5-20 min, transient phosphorylation of ERK 1/2 was observed (2.2 fold at 5 min, 1.9 fold at 10 min, 0.97 fold at 20 min) (Fig. 7) . In addition to ERKs, p38 MAPK phosphorylation was induced by U46619 (10 µM) for 5-20 min (1.8 fold at 5 min, 2.1 fold at 10 min, 2.8 fold at 20 min). CREB phosphorylation at Ser 133 in the same lysates was also monitored. As expected, U46619 induced CREB phosphorylation, correlated with p38 MAPK phosphorylation (5.6 fold at 5 min, 9.1 fold at 10 min, 2.9 fold at 20 min) (Fig. 7) . Gα s coupling to TPs has not currently been reported although an intracellular cAMP concentration by TP agonist is elevated in many cell types. We measured cAMP level after U46619 treatment ( Fig.   8 ). β-Adrenergic receptor agonist, isoproterenol (10 µM) strongly elevated cAMP level.
Comparing with isoproterenol, the effect of U46619 on cAMP accumulation was much weaker, but the significant cAMP increase via TPs was observed. Taken together, these results suggest that PKA and p38 MAPK/MSK pathways are involved in CREB activation and IL-6 gene expression induced by U46619 in 1321N1 cells.
This article has not been copyedited and formatted. The final version may differ from this version. (Huang et al., 2004) . We have shown that TPs associate with at least Gα q and Gα 12 in 1321N1 cells (Honma et al., 1998) . To determine which G-proteins are involved in the signaling pathway leading to IL-6 production, we took an adenoviral approach to interfere with endogenous G-protein functions. The products from adenoviruses that encode the C-terminal regions of Gα q , Gα 12 or Gα 13 inhibited the coupling between these G-proteins and their associated receptors (Arai et al., 2003) . GFP gene is introduced to monitor the infection efficiency of those G-protein interfering mutants. 1321N1 cells infected with those viruses were stimulated with U46619 (10 µM) for 4 h, then RT-PCR was carried out. IL-6 gene expression was promoted with U46619 treatment in 1321N1 cells infected with control virus, and the enhancement was blocked by overexpressing C-terminal regions of Gα q or Gα 13 , (45% and 53% of U46619 (GFP), respectively) but not by Gα 12 (Fig.   9A ). Furthermore, to ask if these G-proteins can affect IL-6 production, the cells were transfected with constitutively active mutants (Gα q Q209L, Gα 12 Q231L and Gα 13 Q226L).
Gα q Q209L and Gα 13 Q226L promoted IL-6 gene expression 15 fold and 7.9 fold, respectively, determined by RT-PCR, while Gα 12 Q231L marginally promoted it (2.6 fold) (Fig. 9B ). In addition, these active mutants could significantly enhance both CRE and IL-6 promoter activities (Fig. 9C ). Taken together, the results suggest that Gα q and Gα 13 are necessary and sufficient for U46619-induced IL-6 gene expression.
Discussion
In the present study, we showed that U46619 promoted IL-6 biosynthesis in 1321N1
human astrocytoma cells and GFAP-positive mouse astrocytes. In addition, U46619 increased CREB activity that was accompanied by its phosphorylation at Ser 133 by PKA and p38
MAPK/MSK, and this CREB activation is essential for IL-6 induction in 1321N1 cells (Fig.   10 ). This is the first report showing TP-mediated IL-6 production in glial cells.
The amount of arachidonic acid metabolites are increased dramatically following brain injury, viral infection or inflammation. These metabolites, including TXA 2 are assumed to play important roles in the CNS under such pathologic conditions. In fact, astrocytes and microglia have the ability to release TXA 2 following activation by bacterial lipopolysaccharide and ATP (Bruner and Murphy, 1993; Minghetti and Levi, 1995; Pearce et al., 1989) . Thus, the elevation of adenine nucleotide concentration or microglial activation after CNS injury or infection may cause the secretion of TXA 2 , leading to activation of TPs on glial cells via autocrine or juxacrine mechanisms. Therefore, a clarification of the physiological roles of TPs in astrocytes will help in identifying therapeutic targets in various CNS disorders.
IL-6 is a pleiotropic factor involved in the regulation of various inflammatory and endocrine functions in both central and periphery nervous systems. In the CNS, although various cell types can produce IL-6, astrocytes play a dominant role in IL-6 production (Gruol and Nelson, 1997). Under normal physiological conditions, IL-6 expression levels in CNS remain low, while IL-6 is up-regulated upon stress, diseases, inflammation or injury. To date, it
This article has not been copyedited and formatted. The final version may differ from this version. production. Abnormal physiological condition often changes the induction of IL-6, such as hypoxia/reoxygenation, generation of reactive oxygen species, viral infections and irradiation.
Not surprisingly, compounds that increase cyclic AMP concentration such as cholera toxin, cyclic AMP analogs and forskolin also lead to an induction of IL-6 in astrocytes (Norris et al., 1994) . Furthermore, phorbol ester and Ca 2+ ionophore, A23187, induced IL-6 production, and both of these reagents caused synergistic production, suggesting that PKC and Ca 2+ signaling are responsible for IL-6 production in rat astrocytes (Norris et al., 1994) . Fiebich et al. (1995) showed that ceramide induced IL-6 gene expression in U373-MG human astrocytoma cells. In terms of transcription factors, IL-6 promoter contains various consensus sequences of transcription factors, indicating that multiple transcription factors influence its gene expression.
For example, CREB, AP-1, NF-κB, C/EBP β (or NF-IL6) and glucocorticoid receptor are known as regulators, and stimuli leading to the activation of these transcription factors are assumed to modulate IL-6 gene expression (Obara and Nakahata, 2002; Sehgal, 1992) .
In the present study, it was demonstrated that U46619 increased the CRE activity by reporter gene assay, accompanied by the phosphorylation of CREB at Ser 133, which is a key regulatory site for its transcription activity (Fig. 3A, 4 , 5 and 7). Furthermore, this CREB This article has not been copyedited and formatted. The final version may differ from this version. and Ginty, 2002) . In our study, to clarify the mechanism leading to CREB activation by U46619, various pharmacological tools were tested. U46619-induced CREB activation was significantly blocked by H89, KT5720 and SB203580 (Fig. 4) . In addition, MSK 1 kinase-dead mutant blocked CRE activity (Fig. 4D) , We previously demonstrated that TPs coupled with the α subunits of at least two heterotrimeric GTP-binding proteins, G q and G 12 in 1321N1 cells (Honma et al., 1998) . By stimulation with TP agonists, phosphoinositide hydrolysis is promoted, followed by increase in intracellular Ca 2+ concentration and PKC activation (Nakahata et al., 1989) . In This article has not been copyedited and formatted. The final version may differ from this version. dbcAMP-treated 1321N1 cells, phosphatidylcholine-specific phospholipase C rather than phosphatidylinositol-specific phospholipase C is predominantly activated by TP agonist, followed by subsequent ERK activation (Kobayashi et al., 2000) . Because carbachol, an agonist of M 3 receptor which couples to G q , did not increase CRE activity nor induce IL-6 expression in this study, it was assumed that the other signaling pathway such as G 12 or G 13 other than G q -mediated PLC pathway may be essential for U46619-induced IL-6 expression.
In fact, although all of constitutively active G-protein mutants (G q , G 12 and G 13 ) could activate CRE and IL-6 promoter, interfering mutants, G q -ct and G 13 -ct, but not G 12 -ct blocked IL-6 gene expression by TP stimulation (Fig. 6 ), indicating that TPs utilize G q and G 13 pathways for IL-6 production. Even though G 12 and G 13 belong to the same heterotrimeric G-protein family, the functional difference between those two G-proteins remain unclear. Nevertheless, in our study, and SQ29548 to TPs. 1321N1 cells were incubated with U46619 (U, 10 µM), U46619+SQ29548 (SQ, 1 µΜ), prostaglandin E 2 (E2, 1 µM), prostaglandin E 2 +SQ29548 or cholera toxin (CTX, 100 µg/ml) for 4 h in serum-free condition, then RT-PCR was performed as described in Experimental Procedures. (D) Effect of U46619 on IL-6 promoter activity in 1321N1 cells. 1321N1 cells were transfected with plasmid encoding IL-6 promoter-luciferase gene. After overnight serum-starvation, the cells were incubated with U46619 (10 µM) or forskolin (10 µM) for 6 h. Luciferase activity was measured as described in Experimental
Procedures. Values are the means + S.E.M. of three determinations. U46619 (10 µM) and forskolin (10 µM) significantly increased IL-6 promoter activity compared with the corresponding control ( * P < 0.05). significantly increased the CRE activity ( * P < 0.05). (B) CRE is essential for IL-6 expression.
After 1321N1 cells were transfected with plasmid encoding wild type (WT) IL-6 promoter-luciferase gene or its CRE-mutant, they were stimulated with U46619 (10 µM) or forskolin (10 µM) for 6 h in the serum-free condition. After the incubation, luciferase assay was performed. Values represent the means + S.E.M for three determinations. U46619 (10 µM) and forskolin (10 µM) significantly increased the IL-6 promoter activity ( * P < 0.05), and mutation at CRE significantly suppressed both activities ( # P < 0.05). MSK1 wild type (WT) or the kinase-dead mutant (KD) (D195A/D565A) was overexpressed in 1321N1 cells, then the cells were stimulated with U46619 (10 µM) for 6 h as performed above.
Values represent the means + S.E.M for three determinations. U46619 significantly increased the CRE activity in the cells overexpressing MSK1 wild type ( * P < 0.05). The effect was blocked by mutations in two kinase-domains ( # P < 0.05). U46619 via PKA and p38 MAPK. 1321N1 cells were stimulated with U46619 (10 µM) for 10 min in the presence or absence of H89 (10 µM), SB203580 (SB, 30 µM) and KT5720 (KT, 2 µM), followed by Western blotting, using antibodies against phospho-CREB and CREB. 
